Drug Use Research & Management Program
OHA Health Systems Division
500 Summer Street NE, E35; Salem, OR 97301-1079
Phone 503-947-5220 | Fax 503-947-1119

Oregon Drug Use Review / Pharmacy & Therapeutics Committee

Thursday, April 3rd, 2025
1:05 PM - 4:15 PM
Via Zoom webinar

MEETING MINUTES

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence, and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee, and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333

Members Present: Stacy Ramirez, PharmD; Bridget Bradley, PharmD; Douglas Carr, MD; Patrick DeMartino, MD; Russ Huffman, PMHNP; Cat Livingston, MD; Eddie Saito, PharmD; Jeanne Savage, MD; Samara Stevens, ND

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD; Megan Herink, PharmD; Deanna Moretz, PharmD; Kathy Sentena, PharmD; Sarah Servid, PharmD; Courtney Ho, PharmD Candidate; Trevor Douglass, DC; Lan Starkweather, PharmD; Brandon Wells; Dee Weston, JD; Jennifer Bowen; Michael Yu, DC; Kyle Hamilton

Audience: Sajani Barot*, Idorsia Pharmaceuticals, Amanda Rendall*, Neurelis; Pam Eads*, UCB; Jay Mehta*, Axsom Therapeutics; Erin Nowak*, Abbvie; Rochelle Yang*, Teva; Marc Parker, Viking; Leif Bruce, Novo Nordisk; Leanne Yantis, AllCare; Cathy Simpson, AbbVie; Jessica Grussing, Neurelis; Ray Kong, Neurocrine Bioscience; Andrea Willcuts, Idorsia; Brett Fushimi, UCB; Dan O'Donnell, Axsome Therapeutics; Kim Eggert; Jennifer Lankford; Georgette Dzwilewski, Indivior; Erin Scow, OHA; Shauna Durbin, CEbP; Jim Slater, CareOregon; Andrea Vintro, CEbP; Jen Tamburo, AstraZeneca; Jennifer Lankford, Eli Lilly; Elva Van Devender, Umpqua Health; Gary Parenteau, Dexcom; Greg Kitchens, Artia Solutions; Melissa Snider, Gilead; Bryan Armstrong, CareOregon; Chris Ferrin, IHN; Nirmal Ghuman, J&J; Lisa Pulver, J&J; Rosalie Elliott, Umpqua Health; Mark Kantor, AllCare Health; Brett Freund; Amy Breen, Teva

(*) Provided verbal testimony

I. CALL TO ORDER

A. Roll Call & Introductions
- Meeting called to order at approx. 1:05 p.m., introductions by Committee and staff

B. Conflict of Interest Declaration – no new conflicts of interest were declared

C. Approval of Agenda and February Minutes presented by Roger Citron, RPh
ACTION: Motion to approve, 2nd, all in favor

D. Department Update provided by Andrew Gibler, PharmD

E. Legislative Update provided by Dee Weston, JD

OREGON HEALTH AUTHORITY

OSU Oregon State University College of Pharmacy

Drug Use Research & Management Program
OHA Health Systems Division
500 Summer Street NE, E35; Salem, OR 97301-1079
Phone 503-947-5220 | Fax 503-947-1119

II. CONSENT AGENDA TOPICS

A. Orphan Drug Policy Updates
Recommendation:
- Update Table 1 in the Orphan Drugs PA criteria to support medically appropriate use of Lenmeldy™ (atidarsagene autotemcel); Ctexli™ (chenodiol); Crenessity™ (crinecefont); Camzyos® (mavacamten); Gomekli™ (mirdametinib) based on their FDA-approved label

III. NEW BUSINESS

A. Drugs for Weight Management PA Update for Obstructive Sleep Apnea: Kathy Sentena, PharmD
Recommendation:
- Amend Weight Management Drugs PA criteria to allow coverage of tirzepatide for patients with OSA and obesity
- Evaluate costs in executive session
ACTION: Motion to approve, 2nd, all in favor

B. Tryvio™ (aprocitentan) New Drug Evaluation: Megan Herink, PharmD
Recommendations:
- Implement PA for aprocitentan to ensure safe and appropriate use
Public Comment: Sajani Barot, Indorsia Pharmaceuticals
ACTION: Motion to approve, 2nd, all in favor

C. Oncology Drug Policy Evaluation: Courtney Ho, PharmD Candidate
Recommendations:
- Continue to require PA for newer antineoplastic medications due to high costs, ongoing accelerated approvals, and no evidence of a barrier to access, or delay in therapy resulting from the PA policy
- Add new FDA-approved antineoplastic agent Romvimza™ (vimseltinib) to Table 1 in the Oncology Agents PA criteria
- Encourage cost effective evidence-based step therapy for certain cancer indications supported by clinical guidelines
ACTION: Motion to approve, 2nd, all in favor

D. Antiepileptics, Noninjectable Class Update: Deanna Moretz, PharmD
Recommendations:
- Retire Clobazam PA criteria based on compendia support for treatment resistant seizures and make at least one formulation of clobazam preferred
- Revise Pregabalin PA criteria to include medically appropriate use for fibromyalgia for patients with the EPSDT Benefit
- Evaluate comparative costs in executive session
Public Comment: Amanda Rendall, Neurelis; Pam Eads, UCB
ACTION: Motion to approve, 2nd, all in favor

E. Headache Prevention and Treatment Class Update: Kathy Sentena, PharmD

Recommendations:

- No changes to the PDL are recommended based on review of the evidence
- Update the CGRP Antagonist and Antimigraine - Serotonin Agonist PA criteria with clerical updates and new drug additions
- Implement the Butalbital Containing Products PA criteria
- Evaluate costs in executive session

Public Comment: Jay Mehta, Axsome Therapeutics; Erin Nowak, Abbvie; Rochelle Yang, Teva

ACTION: The Committee recommended removing question #10 and modifying question #15 to add subcutaneous sumatriptan and intranasal zolmitriptan as an option in the CGRP PA criteria. The Committee also recommended increasing the Symbravo quantity to #9 to match the package size

Motion to approve, 2nd, all in favor

F. Treatments for Hyperhidrosis Class Review: Sarah Servid, PharmD

Recommendations:

- Implement PA criteria for topical anticholinergics and onabotulinumtoxinA to limit use to people with:
    - Diagnosis of primary axillary hyperhidrosis
    - Severe symptoms that interfere with daily activities
    - When prescribed by, or in consultation with, a dermatologist
    - When symptoms have failed to respond to non-pharmacologic lifestyle management
- Recommend onabotulinumtoxinA as a preferred option for treatment of hyperhidrosis based on large treatment effect size and relatively long duration of effect
- Make topical anticholinergics non-preferred

ACTION: Motion to approve, 2nd, all in favor

G. Botulinum Toxins Class Update: Sara Fletcher, PharmD

Recommendations:

- No changes to policy for use in migraine headache, strabismus, or other previously reviewed and funded indications
- Update the Botulinum Toxins PA criteria to incorporate coverage for chronic anal fissures
- Evaluate costs in executive session

IV. EXECUTIVE SESSION

Members Present: Bridget Bradley, PharmD; Douglas Carr, MD; Patrick DeMartino, MD; Russ Huffman, PMHNP; Cat Livingston, MD; Jeanne Savage, MD; Samara Stevens, ND

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD; Deanna Moretz, PharmD; Kathy Sentena, PharmD; Sarah Servid, PharmD; Lan Starkweather, PharmD; Brandon Wells; Kyle Hamilton

V. RECONVENE for PUBLIC RECOMMENDATIONS

OREGON HEALTH AUTHORITY

OSU Oregon State University College of Pharmacy

Drug Use Research & Management Program
OHA Health Systems Division
500 Summer Street NE, E35; Salem, OR 97301-1079
Phone 503-947-5220 | Fax 503-947-1119

A. Drugs for Weight Management

Recommendation: Make Zepbound version of tirzepatide preferred and subject to PA criteria pending acceptance of a SR offer for OSA

ACTION: Motion to approve, 2nd, all in favor

B. Antiepileptics, Noninjectable Class

Recommendations: Make generic clobazam tablets and oral suspension preferred; make pregabalin capsules and generic levetiracetam ER 24H tablets preferred; and make carbamazepine oral suspension non-preferred

ACTION: Motion to approve, 2nd, all in favor

C. Headache Prevention and Treatment Class

Recommendations: Make rizatriptan tablets and rapid tablets, and eletriptan tablets preferred

ACTION: Motion to approve, 2nd, all in favor

D. Botulinum Toxins Class

Recommendations: Remove PDL status for all products

ACTION: Motion to approve, 2nd, all in favor

VI. ADJOURN